Latest news

• BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

  Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive results from a phase 3 trial of their CAR-T cell therapy Abecma (idecabtagene vicleucel)

• BMS and 2seventy bio announce positive results for multiple myeloma treatment

  Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive phase 3 trial top-line results for Abecma (idecabtagene vicleucel) as a treatment for relapsed ... Steve Bernstein, chief medical officer, 2seventy bio,

• BMS and 2seventy bio move away from CAR-T programme

  2021. The decision made by BMS and 2seventy bio reinforces that the companies’ hopes are pinned on Abecma, as the drug has been in high demand. ... Both companies said they anticipated between $250m and $300m in Abecma sales in 2021, with profits to be

• bluebird bio splits to create new oncology firm 2seventy bio

  2seventy bio gets the company’s immune-oncology cell therapies products, while bluebird bio will continue its work on severe genetic diseases. ... As announced earlier this year, Cambridge, Massachusetts-based bluebird bio has spun off its oncology

• bluebird bio provides update on 2seventy bio spin-off

  bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC). ... This reflects bluebird bio’s plans for a spin-off of its oncology programmes and portfolio into